Tag: lung cancer

An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer. Many patients with lung carcinoma harbor mutations in epidermal growth factor receptor (EGFR), and initially show a good response to molecular target drugs, such as gefitinib, which inhibits the EGFR tyrosine kinase. However, recurrence inevitably occurs within a few years because of acquired drug resistance, leading to poor prognosis. Despite the development of new generations of molecular targeted drugs, recurrence and acquired drug resistance remain problematic. Emerging evidence suggests that cancer...